This round of information summarizes 6 innovative enterprises, among which Xingrui Pharmaceutical has completed a B+round of financing focusing on RNA drug research and development, Feimou Medical has promoted the industrialization of personalized full femtosecond systems, Dongnao Medical has deeply cultivated the field of non-invasive brain computer interfaces, Baijun Biotechnology has strategically integrated with Shanghai Hong Kong Zhongke to create a CRO full industry chain service platform, and companies such as Luofang Biotechnology and Pamu Medical have also successfully obtained financing. Fully reflecting the high preference of the capital market for hardcore innovation and clinical value in the field of biomedicine.

1、 Xingrui Pharmaceutical has completed a B+round of financing, led by Source Code Capital and Tencent

On April 14th, RNA innovative drug developer Xingrui Pharmaceutical (Suzhou) Co., Ltd. officially announced the completion of its B+round of financing, led by Source Code Capital and Tencent Investment.

Since its establishment, Xingrui Pharmaceutical has focused on the research and development of RNA core technology. The company’s pipeline covers multiple cutting-edge treatment fields such as infectious disease vaccines, tumor immunity, and metabolic diseases. Among them, the respiratory syncytial virus (RSV) mRNA vaccine STR-V003 has obtained FDA clinical trial approval and conducted clinical experiments. The personalized tumor vaccine STR-V005 and the in vivo CAR-T pipeline STR-P004 have entered the IIT clinical stage, demonstrating good clinical application potential. It is worth noting that Xingrui Pharmaceutical had previously completed over 300 million yuan in Series B financing in October 2025, and successfully completed financing again in just six months. This rapid financing pace fully demonstrates the high recognition and firm confidence of the capital market in its core technological strength, research and development pipeline value, and future development potential.

It is reported that the funds obtained from this round of B+financing will mainly be used for three core directions: firstly, to accelerate the research and development process of RNA innovative drugs and continuously optimize the research and development efficiency of existing pipelines; Secondly, further expand the R&D pipeline layout, enrich the product matrix, and cover more unmet clinical needs; The third is to improve the layout of the extrahepatic targeted delivery platform, relying on the company’s accumulated library of over 3000 new cationic lipid molecules and tens of thousands of lipid nanoparticle (LNP) ratios, to continuously break through the bottleneck of extrahepatic tissue targeted delivery technology.

As a potential unicorn enterprise in China in 2025, Xingrui Pharmaceutical is accelerating the breakthrough of technical barriers in the RNA therapy field, solving unmet clinical needs, injecting new momentum into the innovative development of China’s biopharmaceutical industry, and helping to enhance the global competitiveness of the domestic RNA drug track through independent and controllable targeted delivery technology and a tiered R&D pipeline.

2、 Feimou Medical has completed nearly 100 million yuan angel round financing to promote the construction of personalized full femtosecond systems

Recently, Shenzhen Feimou Medical Equipment Technology Co., Ltd. announced the completion of an angel round financing of nearly 100 million yuan, led by Yuansheng Venture Capital and followed by institutions such as Qingke Holdings. The funds raised will be mainly invested in the iteration of core product technology and the promotion of clinical registration, marking the acceleration of the company’s research and industrialization process in the field of high-end ophthalmic refractive treatment equipment.

Feimou Medical was founded in November 2022, with a clear focus on innovative research and development of next-generation personalized femtosecond technology driven by both technology and products since its inception. The product system of its layout has demonstrated significant advantages in multiple core optical and surgical parameters, directly addressing the precision and personalized difficulties in current clinical refractive surgery, and has the potential to solve practical clinical needs.

It is worth noting that Feimou Medical systematically expanded its intellectual property globally in the early stages of its establishment, laying a solid patent foundation for its products to enter the international market in the future. After this financing, the company’s primary task is to promote the registration and clinical trial stage of its core femtosecond refractive product, and simultaneously expand the research and development pipeline of other ophthalmic diagnosis and treatment products.

Zhang Yao, General Manager of Feimou Medical, stated that the company’s strategy will focus on achieving comprehensive localization breakthroughs in high-end ophthalmic refractive equipment and is committed to expanding into global markets. Ban Bo, a partner of leading investment firm Yuansheng Venture Capital, pointed out that he is optimistic about Feimou Medical’s breakthrough ability in the field of segmented technology, and will continue to empower it to grow into an internationally competitive ophthalmic equipment provider. This round of financing not only injects key development momentum into Feimou Medical, but also reflects the high attention and confidence of the capital market in domestic high-end medical device enterprises with core technology breakthrough capabilities.

3、 Dongnao Medical has completed its seed round financing and is leading the “brain computer interface+high-end medical equipment” track

Recently, Dongnao Medical Technology (Tianjin) Co., Ltd. announced the completion of a seed round financing, exclusively invested by Tianjin Heying Haihe Brain Computer Fund. As an incubation project of the Haihe Laboratory for Brain Computer Interaction and Human Computer Integration, the company focuses on the innovation of non-invasive brain function monitoring technology, and its technical strength has reached the international leading level.

Dongnao Medical has established a systematic product matrix, with at least 4 products being the world’s first. The core products have completed critical certification and formed independent and controllable technical barriers. The company takes “brain computer interface+high-end medical equipment” as the dual wheel drive, achieving deep integration and two-way empowerment of medical engineering, and is committed to creating a non-invasive brain function monitoring solution that covers all scenarios.

This round of financing will focus on product clinical validation, market promotion, and cutting-edge technology reserves, accelerating the landing and deepening of innovative products. The company emphasizes the deep cultivation of technology to promote the transformation of clinical value, providing high-precision and non-invasive tool support for the diagnosis of neurological diseases, surgical monitoring, and brain health management.

The investor Tianjin Heying Haihe Brain Computer Fund stated that Dongnao Medical has significant technological differentiation and clinical necessity in the field of non-invasive brain monitoring. Its product layout is in line with the trend of domestic innovation in high-end medical devices, and is expected to provide patients with better diagnosis and treatment guarantees, with long-term growth potential.

4、 Baijun Biotechnology and Shanghai Hong Kong Zhongke have completed strategic integration and built a preclinical CRO full industry chain service platform

Recently, Baijun Biotechnology and Shanghai Hong Kong Zhongke officially signed a strategic integration agreement in Shanghai, marking the deep collaboration between the two companies with differentiated advantages in the preclinical CRO field. This integration is not simply a business overlay, but a strategic complementarity based on customer structure, technical expertise, and resource capabilities, aiming to create an integrated full industry chain service platform covering “drug discovery preclinical research IND application”.

Baijun Biotechnology has a long-term focus on drug discovery and early development, with over 85% of its revenue coming from overseas markets. It has strong international service experience and compliance capabilities; However, Shanghai Hong Kong Zhongke has a deep foundation in the field of preclinical evaluation in China, with over 90% of domestic customers and scarce experimental animal resources, as well as a mature local registration and application system. After integration, a service model of “internal and external market linkage, seamless upstream and downstream connection” will be formed, significantly reducing communication and time costs for customers to switch between multiple CROs, and improving research and development efficiency and data coherence.

From an industry perspective, this cooperation directly points to the current trend of CRO industry transitioning from “single link price competition” to “full chain value empowerment”. By integrating resources and technology, the new platform can not only provide one-stop solutions, but also enhance service depth in pharmacology, toxicology and other fields with key resources such as animal models, helping innovative pharmaceutical companies accelerate pipeline promotion.

Against the backdrop of rational investment and financing in biopharmaceuticals, with research and development efficiency as the core consideration, CRO platforms with international capabilities, full chain layout, and scarce resource integration are more likely to gain dual recognition from capital and the market, providing solid support for domestic innovative drugs to go global. This integration may trigger further evolution of the preclinical CRO field towards scale and high added value.

5、 Luofang Biotechnology has received tens of millions of seed round financing, opening up a new track for chronic disease treatment

Luofang Biotechnology has successfully completed a seed round financing of tens of millions of yuan, led by Yuanlai Capital and followed by Dart Innovation Seed Fund, marking a crucial step for the company in the field of innovative polymer drug research and development. This round of funding will be focused on advancing preclinical research and IND applications for its cardiovascular calcification treatment pipeline, as well as expanding other chronic disease related projects.

As a biotechnology enterprise specializing in the research and development and transformation of polymer drugs, the core advantage of Luofang Biotechnology lies in the construction of a full chain research and development platform covering “design synthesis evaluation transformation”. This platform originates from the original technology system of major national projects and has the systematic ability to innovate from the source to industrialization, which is expected to significantly improve the success rate of drug development.

In the field of treatment, the company focuses on chronic diseases such as cardiovascular calcification that lack effective etiological therapy. Its developed polymer drugs aim to precisely intervene in the mechanism of disease occurrence and have outstanding clinical value and market potential. The investor Yuanlai Capital is optimistic about its technological strength in leading the development of the new generation of polymer drugs, while the Dart Innovation Seed Fund emphasizes the clinical significance of its deep cultivation in the treatment of calcified diseases and will accelerate the growth of the enterprise through collaborative industrial resources.

This financing not only provides early research and development momentum for Luofang Biotechnology, but also reflects the continuous attention of the capital market to innovative pharmaceutical companies with platform technology and clear clinical positioning, opening up new imaginative space for the application of polymer drugs in the field of chronic disease treatment.

6、 Pamu Medical has completed a $100 million Series D financing, with Medtronic leading the investment and signing a cooperation agreement

On April 20th, Pamu Medical, an innovative medical device company specializing in pulmonary hypertension and heart failure, announced the completion of a $100 million Series D oversubscription financing. This round of financing is led by global medical device giant Medtronic, with existing investors Yin Tuo and Qiming Venture Capital continuing to invest, and Sequoia China and other institutions participating in the investment. Of particular note is that Medtronic and Pamu Medical have simultaneously signed a commercial cooperation agreement aimed at accelerating the application and penetration of innovative therapies in the global market through deep collaboration.

The core product of Pamu Medical – the independently developed pulmonary artery denervation (PADN) system, has demonstrated significant therapeutic potential in clinical practice. This system provides innovative intervention solutions for the urgent clinical demand and limited treatment options of pulmonary hypertension. As of now, approximately 1500 PADN surgeries have been completed worldwide and regulatory approvals have been obtained in seven countries, verifying their safety and effectiveness.

This financing not only injects key funds into Pamu Medical, but also forms strong industry synergy through Medtronic’s strategic leadership and cooperation agreement. The combination of Medtronic’s global business network, market access experience, and innovative technology from Pamu Medical will greatly facilitate the commercialization of PADN systems in core markets such as the European Union, the Middle East, and China.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.